CAS: 18765-09-8; Trioctylsilane

相似化合物

2929-52-4 998-41-4 32395-58-7

上下游产品

CAS号18768-14-4 chloro(tri°Ctyl...

1-溴辛烷置于magnesium,三氯硅烷体系中,用 四氢呋喃 用作溶剂,以3.21 G的收率获得三辛基硅烷
参考文献:应用于液相肽合成的硅基疏水标签:受保护的drgn-1和聚丙氨酸链合成
标题:应用于液相肽合成的硅基疏水标签:受保护的drgn-1和聚丙氨酸链合成
摘要:开发了两种新的可回收硅基疏水标签,用于将它们安装在肽的 C 端,以增加在有机溶剂中的溶解度和液相肽合成 (Lpps) 过程中肽的反应性.它们包含含有甲硅烷氧基的标签和含有芳基甲硅烷基的标签.这些标签的疏水性比以前报道的例子要大得多.含有甲硅烷氧基的标签与fmoc-脱保护条件(fmoc-化学)和氢化条件(cbz-化学)相容,而含有芳基甲硅烷基的标记对fmoc-脱保护条件(fmoc-化学)和boc-脱保护条件具有抗性( Boc-化学).使用含甲硅烷氧基的标签,受保护的 Drgn-1,采用线性合成结合一个收敛合成步骤成功制备了含有14个氨基酸残基的多肽.使用含有芳基甲硅烷基的标签,合成了含有 7 个丙氨酸残基的聚丙氨酸链.含有芳基甲硅烷基的标签也可以安装在 N 端,以将肽从 N 端延伸到 C 端.在这些硅基标签的帮助下,每一步的收率和产品在有机溶剂中的溶解度都非常好.
Doi:10.1039/d2Ob01795D

专利信息

专利号:US-9421532-B2
优先权日:2013-03-01
标 题:Mononuclear iron complex and organic synthesis reaction using same
发明人：NAGASHIMA HIDEO; SUNADA YUSUKE; TSUTSUMI HIRONORI; HASHIMOTO TORU; SAKUTA KOJI
权利人:UNIV KYUSHU NAT UNIV CORP; SHINETSU CHEMICAL CO
摘要:Provided is a mononuclear iron complex that comprises an iron-silicon bond that is represented by formula (1) and that exhibits excellent catalyst activity in each of a hydrosilylation reaction, a hydrogenation reaction, and reduction of a carbonyl compound. n n n n n n n n n n In formula (1), R 1 -R 6 either independently represent an alkyl group, an aryl group, an aralkyl group or the like that may be substituted with a hydrogen atom or X, or represent a crosslinking substituent in which at least one pair comprising one of R 1 -R 3 and one of R 4 -R 6 is combined. X represents a halogen atom, an organoxy group, or the like. L represents a two-electron ligand other than CO. When a plurality of L are present, the plurality of L may be the same as or different from each other. When two L are present, the two L may be bonded to each other. n and m independently represent an integer of 1 to 3 with the stipulation that n+m equals 3 or 4.

专利号:US-9884316-B2
优先权日:2014-03-10
标题:Mononuclear ruthenium complex and organic synthesis reaction using same
发明人：NAGASHIMA HIDEO; SUNADA YUSUKE; OGUSHI HAJIME; SAKUTA KOJI
权利人:UNIV KYUSHU NAT UNIV CORP; SHINETSU CHEMICAL CO
摘要:A neutral or cationic mononuclear ruthenium divalent complex represented by formula (1) can actualize exceptional catalytic activity in at least one reaction among a hydrosilylation reaction, hydrogenation reaction, and carbonyl compound reduction reaction. n n(In the formula, R 1 -R 6 each independently represent a hydrogen atom or an alkyl group, aryl group, aralkyl group, organooxy group, monoorganoamino group, diorganoamino group, monoorganophosphino group, diorganophosphino group, monoorganosilyl group, diorganosilyl group, triorganosilyl group, or organothio group optionally substituted by X; at least one pair comprising any of R 1 -R 3 and any of R 4 -R 6 together represents a crosslinkable substituent; X represents a halogen atom, organooxy group, monoorganoamino group, diorganoamino group, or organothio group; L each independently represent a two-electron ligand other than CO and thiourea ligands; two L may bond to each other; and m represents an integer of 3 or 4.)

专利号:US-10363551-B2
优先权日:2015-03-09
标 题:Mononuclear iron complex and organic synthesis reaction using same
发明人：NAGASHIMA HIDEO; SUNADA YUSUKE; SAWANO Mina; NODA DAISUKE; SAKUTA KOJI
权利人:UNIV KYUSHU NAT UNIV CORP; SHINETSU CHEMICAL CO
摘要:A mononuclear iron bivalent complex having iron-silicon bonds, which is represented by formula (1), can exhibit an excellent catalytic activity in at least one reaction selected from three reactions, i.e., a hydrosilylation reaction, a hydrogenation reaction and a reaction for reducing a carbonyl compound. n n n n n n n n n n (In the formula, R 1 to R 6 independently represent a hydrogen atom, an alkyl group which may be substituted by X, or the like; X represents a halogen atom, or the like; L 1 represents at least one two-electron ligand selected from an isonitrile ligand, an amine ligand, an imine ligand, a nitrogenated heterocyclic ring, a phosphine ligand, a phosphite ligand and a sulfide ligand, wherein, when multiple L 1 's are present, two L 1 's may be bonded to each other; L 2 represents a two-electron ligand that is different from a CO ligand or the above-mentioned L 1 , wherein, when multiple L 2 's are present, two L 2 's may be bonded to each other; and m 1 represents an integer of 1 to 4 and m 2 represents an integer of 0 to 3, wherein the sum total of m 1 and m 2 (i.e., m 1 +m 2 ) satisfies 3 or 4.)

专利号:EP-1040098-B1
优先权日:1997-12-17
标题:Integrin receptor antagonists
发明人：ASKEW BEN C; COLEMAN PAUL J; DUGGAN MARK E; HALCZENKO WASYL; HARTMAN GEORGE D; HUNT CECILIA; HUTCHINSON JOHN H; MEISSNER ROBERT S; PATANE MICHAEL A; SMITH GARRY R; WANG JIABING
权利人:MERCK & CO INC
摘要:The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors alpha nu beta 3, alpha nu beta 5, and/or alpha nu beta 6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

专利号:US-6784190-B2
优先权日:1997-12-17
标 题 :Integrin receptor antagonists
发明人：ASKEW BEN C; COLEMAN PAUL J; DUGGAN MARK E; HALCZENKO WASYL; HARTMAN GEORGE D; HUNT CECILIA A; HUTCHINSON JOHN H; MEISSNER ROBERT S; PATANE MICHAEL A; SMITH GARRY R; WANG JIABING
权利人:MERCK & CO INC
摘要:The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors alphavbeta3, alphavbeta5, and/or alphavbeta6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

专利号:KR-20100042276-A
优先权日:2007-07-06
标题 :Synthesis method of substituted tetracycline compound